BDTX vs. PGEN, XNCR, OCS, ORKA, BGM, MNMD, VALN, PROK, ANAB, and KURA
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Precigen (PGEN), Xencor (XNCR), Oculis (OCS), Oruka Therapeutics (ORKA), BGM Group (BGM), Mind Medicine (MindMed) (MNMD), Valneva (VALN), ProKidney (PROK), AnaptysBio (ANAB), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs. Its Competitors
Precigen (NASDAQ:PGEN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.
Black Diamond Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -2,868.66%. Black Diamond Therapeutics' return on equity of 12.70% beat Precigen's return on equity.
In the previous week, Precigen had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 5 mentions for Precigen and 4 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Precigen's score of 0.48 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Black Diamond Therapeutics has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
33.5% of Precigen shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 47.1% of Precigen shares are owned by company insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Precigen has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500.
Precigen presently has a consensus target price of $8.25, indicating a potential upside of 133.71%. Black Diamond Therapeutics has a consensus target price of $9.60, indicating a potential upside of 131.33%. Given Precigen's higher probable upside, equities analysts plainly believe Precigen is more favorable than Black Diamond Therapeutics.
Summary
Black Diamond Therapeutics beats Precigen on 12 of the 16 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 10/16/2025 by MarketBeat.com Staff
